lnnovation, expertise and commitment are the basis for our work. Since the founding of Octapharma Biopharmaceuticals GmbH in 1997, our experience in the area of research, development and production has evolved extensively, resulting in the maturation of an effective, product-oriented biotechnology fi rm. Our core competence is the development of recombinant protein pharmaceuticals as a modern alternative to plasma products. Our primary goal is the development of therapeutic protein products that resemble the native protein present in human tissues or blood for best tolerability and function in our patients. The aim is to develop therapeutic proteins with an improved compatibility (e.9. by securing human post-translational modifications), prolonged half-life in circulation, and to develop convenient routes of administration. Thus, Octapharma Biopharmaceuticals has implemented all applicable GMP requirements into production, storage and laboratories to ensure the highest and safest quality of our products for the patients.